(Q35753383)

10 August 2017

1 reference

title

A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis (English)

1 reference

10 August 2017

0 references

Richard E Gonsette

1

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Expert Opinion on Pharmacotherapy

10 August 2017

published in

1 reference

10 August 2017

volume

5

1 reference

10 August 2017

issue

4

1 reference

10 August 2017

page(s)

747-765

1 reference

Analysis of CD40-CD40 ligand interactions in the regulation of human B cell function.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Identification of autoantibodies associated with myelin damage in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Suppression of experimental allergic encephalomyelitis by mitoxantrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Mitoxantrone immunotherapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Treatment of Marburg Variant Multiple Sclerosis with Mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Decrease in heart ventricular ejection fraction during multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Non-Invasive Functional and Biochemical Assessment of Mitoxantrone Cardiotoxicity in Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Severe heart failure in a young multiple sclerosis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Acute Myelogenous Leukemia Following Xmitoxantrone Treatment for Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Cardiovascular toxicity with cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Side effects of immunosuppressant therapies used in neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Tolerogenic immunosuppression for organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Early intervention in multiple sclerosis : better outcomes for patients and society?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.4.747

21 January 2018

Identifiers

DOI

10.1517/14656566.5.4.747

1 reference

10 August 2017

1 reference